Search Results - "Jodon, Gray"

Chronic diarrhoea and ichthyosis vulgaris: a rare presentation of Hodgkin's lymphoma by Allen, Jessica Michelle, Simpson, Haley M, Jodon, Gray

“…A man in his 30s presented with several months of non-bloody diarrhoea and nausea along with conjunctivitis, diffuse ichthyosis and cellulitis in the setting…”
Get more information

Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving CAR-T Cell Therapy by Jodon, Gray, Colton, Meryl, Abbott, Diana, Cai, Anthony, Haverkos, Brad M., Morgan, Rustain, Kamdar, Manali

“…Introduction: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of relapsed/refractory (R/R) B-cell lymphomas. Despite this…”
Get full text

The impact of BMI on post-operative survival in bladder cancer patients by Jodon, Gray, Kessler, Elizabeth Riley, Smith, Derek, Wilson, Shandra

“…Abstract only…”
Get full text

Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy by Jodon, Gray, Colton, Meryl D., Abbott, Diana, Cai, Anthony, Haverkos, Bradley, Morgan, Rustain, Kamdar, Manali

“…Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of relapsed/refractory (R/R) B-cell lymphomas, though certain patients do not…”
Get full text

Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors by Jodon, Gray, Fischer, Stacy M., Kessler, Elizabeth R.

“…Urothelial carcinoma, or bladder cancer, is a malignancy that most commonly affects older patients. The median age at diagnosis is 73 years, and care of these…”
Get full text

A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma by Cortese, Matthew J., Wei, Wei, Cerdeña, Sebastian, Watkins, Marcus P., Olson, Marissa, Jodon, Gray, Kaiser, Jeff, Haverkos, Bradley, Hughes, Mitchell E., Namoglu, Esin, Grover, Natalie S., Snow, Anson, Orellana-Noia, Victor, Rainey, Magdalena, Sohail, Mohammad, Rudoni, Joslyn, Portell, Craig, Voorhees, Timothy, Landsburg, Daniel J., Kamdar, Manali, Kahl, Brad S., Hill, Brian T.

“…Patients with double- and triple-hit lymphomas (DHL/THL) have inferior outcomes with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone…”
Get full text

A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma by Cortese, Matthew J, Wei, Wei, Cerdena, Sebastian, Watkins, Marcus, Olson, Marissa, Jodon, Gray, Kaiser, Jeff, Haverkos, Bradley, Hughes, Mitchell E., Grover, Natalie S, Snow, Anson, Orellana-Noia, Victor M., Rainey, Magdalena A, Sohail, Mohammad Ahsan, Rudoni, Joslyn, Portell, Craig A., Voorhees, Timothy J, Landsburg, Daniel J., Kamdar, Manali, Kahl, Brad S., Hill, Brian T.

“…BACKGROUND: High-grade B-cell lymphomas (HGBLs) with rearrangement of MYC and BCL2 and/or BCL6, known as “double-hit” or “triple-hit” B-cell lymphomas…”
Get full text

Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma by Sohail, Mohammad Ahsan, Li, Hong, Wei, Wei, Cerdena, Sebastian, Watkins, Marcus, Olson, Marissa, Jodon, Gray, Kaiser, Jeff, Haverkos, Bradley, Hughes, Mitchell E., Grover, Natalie S, Snow, Anson, Orellana-Noia, Victor M., Rainey, Magdalena A, Cortese, Matthew J, Rudoni, Joslyn, Portell, Craig A., Voorhees, Timothy J, Landsburg, Daniel J., Kamdar, Manali, Kahl, Brad S., Hill, Brian T.

“…BACKGROUND: Central nervous system (CNS) relapse in systemic non-Hodgkin's lymphoma is associated with a guarded prognosis with a median survival of only 2-6…”
Get full text